...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Third Eye, AHA, US Listing
8
Sep 08, 2019 08:35AM
5
Sep 08, 2019 12:36PM
4
Sep 08, 2019 01:33PM
3
Sep 08, 2019 07:58PM
4
Sep 11, 2019 03:03PM
1
Sep 11, 2019 03:08PM
2
Sep 11, 2019 03:11PM
3
Sep 11, 2019 03:22PM
2
Sep 11, 2019 03:32PM
1
Sep 11, 2019 03:47PM
1
Sep 11, 2019 04:13PM
5
bfw
Sep 11, 2019 04:18PM
2
Sep 11, 2019 04:25PM
8
Sep 11, 2019 05:16PM
6
Sep 11, 2019 06:04PM
6
Sep 11, 2019 06:52PM
1
Sep 11, 2019 07:42PM
4
Sep 11, 2019 08:00PM
1
Sep 11, 2019 08:39PM
2
Sep 11, 2019 09:05PM
4
Sep 11, 2019 10:09PM
2
Sep 11, 2019 10:54PM
9
Sep 11, 2019 11:19PM
4
Sep 12, 2019 03:57AM
3
Sep 12, 2019 05:53AM
7
Sep 12, 2019 09:44AM
3
Sep 19, 2019 08:07AM
1
Sep 19, 2019 08:48AM

Carman....Why are you asking the exact same question again after I already responded to you? Here's your answer again:

Top-line data availability is not required for a trial to be considered and given a late breaking clinical trial presentation. Perfect example.....Amarin's REDUCE-IT trial. 

Amarin announced their AHA 2018 late breaker on September 12th, 2018 but didn't announce REDUCE-IT top-line until September 24, 2018.

Late breaking (and non-late breaking) presentations can be for stellar, so-so, or failed trials results. There are examples of each out there. If you don't believe me, go back through archives of past AHA, ADA, ESC, EASD, and ACC conferences.

BearDownAZ

1
Sep 19, 2019 10:47AM
Share
New Message
Please login to post a reply